A clinical performance study for testing FFPE tissue samples, with therascreen® KRAS RGQ PCR kit, to determine KRAS G12C mutation for potential enrollment into clinical study BO45217 - Performance study: KRAS G12C mutation for enrollment into study BO45217
/ RecruitingNot Applicable AN OPEN-LABEL, MULTICENTER, PHASE I STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY CLINICAL ACTIVITY OF RO7428731 IN PARTICIPANTS WITH GLIOBLASTOMA EXPRESSING MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III - EGFRvIII - BP42573
/ RecruitingNot Applicable A PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON*S DISEASE - BP43176 IZD334
100 Clinical Results associated with Roche Nederland BV
0 Patents (Medical) associated with Roche Nederland BV
100 Deals associated with Roche Nederland BV
100 Translational Medicine associated with Roche Nederland BV